Indian Dermatology Online Journal · 2019 · 43 citations · 11 references
Veterinary MedicineDermatologyInfectious DiseasesImmunizationImmunotherapyVaccinologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyVaccine-based ImmunotherapyVaccine-preventable DiseasesAdjuvant Intralesional TherapyLikert Scale DesignMeasles-mumps-rubella VaccinationMumps VaccinationPatient Satisfaction AnalysisPatient Satisfaction Evaluation
BACKGROUND: Most therapeutic modalities for common warts remain unsatisfactory. OBJECTIVES: To evaluate efficacy and safety of intralesional MMR (measles, mumps, rubella virus) vaccine in the treatment of common warts in adults. PATIENTS AND METHODS: There were 110 (M:F = 61:49) patients aged 19-62 years having 1-211 warts over dorsal hands, feet, palms, soles, and periungual skin for 1-252 months. MMR vaccine 0.25 mL was injected intralesionally in the largest wart and repeated at 2-week interval until complete clearance or maximum of five doses. The outcome was evaluated as complete clearance, excellent, good, or unsatisfactory response on visual analog scale at every visit and at 4 and 8 weeks, thereafter by comparing baseline clinical photograph. Likert scale was used for patient satisfaction level assessment similarly. RESULTS: Only 51 patients completed the study and 42 (82.4%) of them showed complete clearance of warts and 9 (17.6%) patients showed good or unsatisfactory response. In 4 (7.8%) patients, the warts subsided completely after one dose itself. The four patients showing excellent response after five doses initially also continued to improve during follow-up period of 8 weeks. Except for injection site pain, no adverse effects were noted. There was no recurrence of warts among cured who were also very much satisfied from treatment. CONCLUSION: Despite variable results, intralesional MMR vaccine immunotherapy appears another possible safe and effective treatment option for common warts in a set of adult patients with advantages of regression of distant warts, no significant adverse effects and low recurrence. However, well-designed, controlled studies for minimum effective dose and treatment schedule are highly desirable to make any recommendation.
11
Cutaneous warts: an evidence-based approach to therapy.
Rocky Bacelieri, Sandra Marchese Johnson · PubMed · 2005 · 183 citations
Medicine, Dermatology, Pediatrics +11
One‐Year Experience with Candida Antigen Immunotherapy for Warts and Molluscum
Mandi Maronn, Cindy Salm, Valerie B. Lyon et al. · Pediatric Dermatology · 2008 · 114 citations
Maha Adel Shaheen, Samar Abdallah Mohamed Salem, Dina Fouad et al. · Dermatologic Therapy · 2015 · 108 citations